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After a long battle with prostate cancer, Tom Connors died in his
sleep, during the early hours of Monday 4th February: a true irony
for someone whose research had contributed so much to the ﬁght
against cancer and who had made such an outstanding contribu-
tion to the whole cancer research community.
Tom was, without doubt, one of the best known and most
popular ﬁgures in cancer research. He had been involved in the
development of new anti-cancer drugs for 40 years and for the last
30 years he was one of the world’s leading authorities. During his
career he served on just about every National and International
Committee of importance in his ﬁeld and he had chaired most
of them. He was the only non-American to ever serve on the Presi-
dent’s advisory committee.
He was a member of the Editorial Board of the British Journal
of Cancer for many years. Tom could be relied upon as a referee
who would always give an honest and unbiased opinion.
Born in Mortlake, on the Thames west of London, in 1934, Tom
was educated at Wimbledon College and University College
London, graduating with a Special Physiology Honours degree in
1957. It was then that a family friend, one of the most eminent
chemists ever to work in the ﬁeld, the late Professor Walter Ross,
persuaded him to consider cancer research as a career and to study
with him at the Chester Beatty Research Institute. This Tom did,
gaining his PhD in organic chemistry in 1960. So began his career
in experimental cancer chemotherapy. Later his career would
expand into toxicology, where he made a major contribution, gain-
ing respect and admiration of the toxicology community. Between
1976 and 1991 he was the Director of the Medical Research Coun-
cil’s Toxicology Unit. Tom was a superb communicator and
teacher; many of us have learned a great deal from him, at all
stages of our careers. However, I do not think any of us have
learned to be quite so bright and sparkling after a night drinking
with him.
Always a great listener, Tom was receptive to new ideas and
suggestions. But those of us who knew him well knew that his
responses, whilst polite and constructive, were generally short
and left no doubts of his opinion. A good idea would always be
‘brilliant’, anything less would be ‘interesting’. Many of today’s
senior cancer research workers passed through his hands, as
students, post-doctoral fellows or visiting workers. His message
was simple: without a sound understanding of the biology of the
cancer process and the pharmacology of anti-cancer agents, it
would be impossible to develop more effective anti-cancer thera-
pies. His emphasis on this message within the scientiﬁc
community was greatly appreciated by his clinical colleagues and
has served to bring a unity of purpose to the whole process of
developing new anti-cancer drugs.
It is difﬁcult to single out speciﬁc achievements from the
many in his scientiﬁc career. But his work with cis-platinum
and its derivative carboplatin, two of the most effective anti-
cancer agents, is recognised as outstanding. Tom Connors was
the ﬁrst person to evaluate the antitumour potential of cisplatin
and his initiative led to its ﬁrst clinical trials at the Royal Mars-
den Hospital. Later, in collaboration with the late John Roberts,
he conducted fundamental studies into its mechanism of action.
This in turn, led to the development of carboplatin, a derivative
with good anti-cancer activity but with fewer unpleasant side
effects.
During a long association with The Cancer Research Campaign,
he served as Chairman of the Scientiﬁc Committee and the Grants
Committee and several other important sub-committees. However,
his most inspired role was in the formation of the CRC Phase I/II
Drug Development Committee. The work of this committee has
made Great Britain the world leader in the development of new
anti-cancer drugs. Tom also served on the Committee of Manage-
ment of the Institute of Cancer Research and on the Board of
Governors of the Royal Marsden Hospital.
Tom will be remembered by many for his involvement in the
British Association for Cancer Research (BACR). He attended
nearly every BACR meeting after joining it in 1969. In 1990 he
became Chairman of the BACR Executive Committee, a position
that allowed him to play a major role in developing the Associa-
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was instrumental in setting standards of excellence in the clinical
and laboratory research presented at its annual meetings. His
commitment to the BACR led to him being chosen as its Presi-
dent in 1994. Usually Presidents are merely ﬁgureheads, but
Tom continued to involve himself in many aspects of the activ-
ities of the Association. His interaction with the younger
members culminated in his co-producing the famous BACR
Song-Book in 1995.
In 1997, to mark his services to the BACR and in recognition of
his contribution to cancer research, the Executive Committee
proposed that a special lecture should be presented at the Annual
Meeting of the Association: ‘The Tom Connors Award Lecture’.
This has now been presented four times by British speakers of
international repute.
On his retirement, in 1994, Tom took up an appointment as
Honorary Professor at the School of Pharmacy, University of
London. From this position, and in his own time, he continued
to make a major contribution to the development of new anti-
cancer drugs. He served on many committees, made active contri-
butions to scientiﬁc meetings and willingly gave his advice and
guidance to others. Tom received many scientiﬁc and academic
accolades, including honorary degrees from several universities
and awards from learned societies. Sadly, he never received the
wider public recognition that many felt he richly deserved.
His passing leaves a tremendous gap in the cancer research
community. He will be sadly missed and warmly remembered by
all the friends and colleagues who were privileged to know him
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